Fast Five Quiz: The Recurrence Risks for Breast Cancer

Elwyn C. Cabebe, MD


February 08, 2022

ER–positive (ER+)/progesterone receptor–positive (PR+)/human epidermal growth factor receptor 2–negative (HER2-) breast cancer is predictive of late recurrence (more than 5 years after diagnosis), especially in patients with high ER titer and low nuclear grade. Most breast cancer relapses, however, occur within the first 5 years after diagnosis. In triple-negative breast cancer, most recurrences happen within 3 years after diagnosis.

Childbearing after treatment for invasive breast cancer does not increase rates of recurrence.

Although statin use has been associated with a reduced risk for distant breast cancer recurrence, no such association has been found for locoregional breast cancer recurrence.

Learn more about breast cancer recurrence risk.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.